Abstract Background The World Heart Federation has undertaken an initiative to develop a
series of Roadmaps to promote development of national policies and health systems …

Purpose The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety,
and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Venous thromboembolism (VTE) is associated with high recurrence, mortality, and cost
burden. Direct oral anticoagulants (DOACs) are currently used for VTE treatment, and they …

心房颤动(简称房颤) 近年来的发病率呈现年轻化趋势, 严重威胁着人类的生存及健康.
基于决策树‒马尔可夫模型, 模拟房颤‒脑卒中‒疾病转归的自然发展过程, 依据成本效用等指标 …

Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …

Los pacientes con enfermedad renal crónica (ERC) tienen tendencias hemorrágicas y
trombóticas, por lo que la indicación de anticoagulación ante la aparición de fibrilación …

Background: Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …

Background: Atrial fibrillation (AF) affects 0.5% to 2.0% of the general population and is
usually associated with cardiac structural diseases, hemodynamic damage, and …

Introduction Warfarin continues to be the most widely used anticoagulant in clinical practice
around the world for the prevention of thromboembolic events in patients with atrial …